Understanding and targeting cancer growth pathways
Decoding and Targeting the PI3K-mTOR Signaling Network in Cancer
This study is looking at how certain pathways in our cells help cancer grow, with the hope of finding new ways to treat cancer that could lead to more personalized care for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harvard School of Public Health NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10865109 on NIH RePORTER |
What this research studies
This research investigates how specific signaling pathways, particularly the PI3K and mTOR pathways, contribute to the growth and proliferation of cancer cells. By examining the molecular mechanisms that activate these pathways, the research aims to identify potential targets for new cancer therapies. The approach includes developing innovative genetic mouse models to study these pathways in detail, which could lead to breakthroughs in understanding cancer biology and treatment options. Patients may benefit from insights gained that could inform personalized treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with cancers that are driven by the PI3K and mTOR signaling pathways.
Not a fit: Patients with cancers unrelated to the PI3K or mTOR pathways may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that improve treatment outcomes for cancer patients.
How similar studies have performed: Previous research has shown promising results in targeting the PI3K and mTOR pathways in cancer treatment, indicating that this approach has potential for success.
Where this research is happening
Boston, United States
- Harvard School of Public Health — Boston, United States (Active)
Researchers
- Principal investigator: Manning, Brendan D. — Harvard School of Public Health
- Study coordinator: Manning, Brendan D.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.